Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates
Related Experiment Videos
Insights
Intravenous immunoglobulin (IVIG) therapy effectively prevents infections in high-risk preterm infants. This safe treatment significantly reduced infection rates and mortality in very low birth weight neonates.
Area of Science:
- Neonatal Medicine
- Immunology
- Pediatric Infectious Diseases
Background:
- High-risk neonates are susceptible to infections.
- Prophylaxis of infection is crucial for improving neonatal outcomes.
Purpose of the Study:
- To evaluate the safety and effectiveness of intravenous immunoglobulin (IVIG) therapy for infection prophylaxis in high-risk neonates.
Main Methods:
- A randomized controlled trial involving 133 high-risk neonates stratified into two groups.
- Group 1: Birth weight ≤ 1500g and gestational age ≤ 34 weeks. Group 2: Birth weight > 1500g requiring intensive care and ventilation.
- Treatment group received IVIG (0.5 g/kg/wk) for 1 month (Group 1) or during intensive care (Group 2). Control groups received no IVIG.
Main Results:
- In Group 1 (very low birth weight infants), IVIG treatment reduced infection incidence from 77% to 51% (P<0.02) and septicemia from 20% to 5% (P<0.05).
- Mortality due to infection was significantly lower in treated Group 1 infants (1 vs. 6, P<0.04).
- No significant differences in infection or septicemia rates were observed in Group 2 (larger infants). IVIG was safe with no observed side effects.
Conclusions:
- Intravenous immunoglobulin therapy is safe and effective for preventing infections in preterm, very low birth weight infants.
- IVIG demonstrated significant benefits in reducing infection and septicemia rates in this vulnerable neonatal population.
- Further research may be warranted for IVIG use in larger, critically ill neonates.
Abstract:
The safety and effectiveness of intravenously administered gammaglobulin therapy for prophylaxis of infection was evaluated in 133 high-risk neonates. The infants were stratified into two groups: infants with birth weight less than or equal to 1500 g and gestational age less than or equal to 34 weeks, and infants with birth weight greater than 1500 g and receiving intensive care and assisted ventilation. Forty-three infants in group 1 and 25 in group 2 were given gammaglobulin at a dose of 0.5 g/kg/wk, for 1 month in group 1 and during intensive care in group 2. Forty infants in group 1 and 25 in group 2 served as controls. Serum total IgG and group B streptococcus-, Escherichia coli-, and CMV-specific IgG levels similar to those in adult controls were observed in the treated infants 2 hours after gammaglobulin administration. In the treated infants in group 1, the incidence of infection was 51%, and of septicemia 5%; in the controls the incidence of infection was 77% (P less than 0.02), and of septicemia 20% (P less than 0.05). Infection was the main cause of death in one treated and six control infants in group 1 (P less than 0.04). In the infants with birth weight greater than 1500 g receiving intensive care and assisted ventilation, no significant differences were observed in the incidence of infection or septicemia in treated and control infants. No side effects were observed after intravenous gammaglobulin administration. These data show that intravenously administered gammaglobulin is both safe and effective for prophylaxis of infection in preterm very low birth weight infants.